Antiretroviral therapy coverage for PMTCT in Zimbabwe

Zimbabwe: Antiretroviral therapy coverage for PMTCT was 93.0% in 2024. ◆ Volatile

Latest (2024)
93.0%
Change on year
up 2.2%
World rank
20th
of 84 countries
All-time high
95.0%
in 2019
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Antiretroviral therapy coverage for PMTCT in Zimbabwe, 2000–2024

0204060801002000201220242000: 0 % of pregnant women living with HIV2001: 0 % of pregnant women living with HIV2002: 2 % of pregnant women living with HIV2003: 8 % of pregnant women living with HIV2004: 7 % of pregnant women living with HIV2005: 11 % of pregnant women living with HIV2006: 13 % of pregnant women living with HIV2007: 22 % of pregnant women living with HIV2008: 36 % of pregnant women living with HIV2009: 43 % of pregnant women living with HIV2010: 29 % of pregnant women living with HIV2011: 48 % of pregnant women living with HIV2012: 74 % of pregnant women living with HIV2013: 73 % of pregnant women living with HIV2014: 81 % of pregnant women living with HIV2015: 81 % of pregnant women living with HIV2016: 87 % of pregnant women living with HIV2017: 91 % of pregnant women living with HIV2018: 94 % of pregnant women living with HIV2019: 95 % of pregnant women living with HIV2020: 90 % of pregnant women living with HIV2021: 87 % of pregnant women living with HIV2022: 86 % of pregnant women living with HIV2023: 91 % of pregnant women living with HIV2024: 93 % of pregnant women living with HIV

Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of pregnant women living with HIV.

Analysis

The most recent figure for antiretroviral therapy coverage for pmtct in Zimbabwe is 93.0%, measured in 2024.

The figure is up 2.2% on the previous year and up 14.8% over ten years.

Over the whole period, antiretroviral therapy coverage for pmtct in Zimbabwe peaked at 95.0% in 2019 and was at its lowest, 0.0%, in 2000.

Zimbabwe ranks 20th of 84 countries on this measure, in the top quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Antiretroviral therapy coverage for PMTCT in Zimbabwe, year by year

Annual values for Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) in Zimbabwe, 2000 to 2024.
Year % of pregnant women living with HIV Change
2000 0.0%
2001 0.0%
2002 2.0%
2003 8.0% +300.0%
2004 7.0% -12.5%
2005 11.0% +57.1%
2006 13.0% +18.2%
2007 22.0% +69.2%
2008 36.0% +63.6%
2009 43.0% +19.4%
2010 29.0% -32.6%
2011 48.0% +65.5%
2012 74.0% +54.2%
2013 73.0% -1.4%
2014 81.0% +11.0%
2015 81.0% +0.0%
2016 87.0% +7.4%
2017 91.0% +4.6%
2018 94.0% +3.3%
2019 95.0% +1.1%
2020 90.0% -5.3%
2021 87.0% -3.3%
2022 86.0% -1.1%
2023 91.0% +5.8%
2024 93.0% +2.2%

Zimbabwe compared with similar countries

  • Zimbabwe's 93.0% is above the median for lower middle income countries, which is 83.5%, 1.1× the median. (32 countries reporting)
  • Zimbabwe's 93.0% is above the median for Sub-Saharan Africa, which is 82.0%, 1.1× the median. (41 countries reporting)

Biggest year-on-year movements

Years where Antiretroviral therapy coverage for PMTCT in Zimbabwe changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2003 +300.0% 2.0% 8.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 14.2% 0.0% 43.0% 10
2010s 75.3% 29.0% 95.0% 10
2020s 89.4% 86.0% 93.0% 5

Countries ranked near Zimbabwe

  1. 18 Lesotho 94.0% compare
  2. 18 Senegal 94.0% compare
  3. 20 Sierra Leone 93.0% compare
  4. 22 Canada 92.0% compare
  5. 22 Ethiopia 92.0% compare
  6. 22 Tajikistan 92.0% compare

See the full ranking of 99 places →

More health data for Zimbabwe

All data for Zimbabwe →

Frequently asked questions

What is antiretroviral therapy coverage for pmtct in Zimbabwe?
Antiretroviral therapy coverage for pmtct in Zimbabwe was 93.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
What is the highest antiretroviral therapy coverage for pmtct recorded in Zimbabwe?
The highest recorded value was 95.0% in 2019.
What is the lowest antiretroviral therapy coverage for pmtct recorded in Zimbabwe?
The lowest recorded value was 0.0% in 2000.
How does Zimbabwe rank for antiretroviral therapy coverage for pmtct?
Zimbabwe ranks 20th out of 84 countries with data for 2024.
Is antiretroviral therapy coverage for pmtct rising or falling in Zimbabwe?
Over the last ten years it is up 14.8%. The long-run trend across the full record is volatile.
Where does this Zimbabwe data come from?
The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Antiretroviral therapy coverage for PMTCT in Zimbabwe. Statizoid, drawing on UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved 17 September 2026, from https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/zimbabwe/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/zimbabwe/">Antiretroviral therapy coverage for PMTCT in Zimbabwe</a> — Statizoid

About this data

Indicator
Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)
Unit
% of pregnant women living with HIV
Source
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS)
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
99 places, 2,393 data points, 2000–2024
Last refreshed

Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).